LiDCO Group Plc announced that it has received regulatory approval for LiDCOrapid v3, the Company's latest cardiac output monitor with non-invasive technology, for commercial sale in South Korea. The Korean Ministry of Food and Drug Safety has formally approved the Company's hemodynamic monitoring product for commercial sale in South Korea and it will be sold via LiDCO's distribution partner Globaluck Ltd, a medical device sales group specialising in anesthesia and patient monitoring. LiDCO, via its distribution partner, will launch LiDCOrapidv3 at the 39th Annual Congress Korean Society of Critical Care Medicine which will be held in Seoul, South Korea on the 26 April 2019.